Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen

Osteoarthritis and Cartilage

Volumn 15, Issue 3, 2007, Pages 335-342

  Olsen, A K ^a   Sondergaard, B C ^a   Byrjalsen, I ^a   Tanko, L B ^b   Christiansen, C ^b   Muller A ^c   Hein, G E ^c   Karsdal, M A ^a   Qvist, P ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Arthritis; C telopeptide of type II collagen; Chondrocyte function; Matrix metalloproteinase; N terminal propeptide of type II collagen

Indexed keywords

AMINO TERMINAL COLLAGEN TYPE 2 PROPEPTIDE; CARBOXY TERMINAL COLLAGEN TYPE 2 TELOPEPTIDE; COLLAGEN TYPE 2; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOSTATIN M; SOMATOMEDIN C; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTHROPATHY; ARTICLE; ARTICULAR CARTILAGE; BIOCHEMISTRY; BIOSYNTHESIS; CARTILAGE CELL; CARTILAGE DEGENERATION; CATABOLISM; CELL STIMULATION; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONTROLLED STUDY; COW; EX VIVO STUDY; EXPLANT; FEMALE; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RHEUMATOID ARTHRITIS; SUPERNATANT;

ANIMALS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; CATTLE; CHONDROCYTES; COLLAGEN TYPE II; INSULIN-LIKE GROWTH FACTOR I; PEPTIDES; PROCOLLAGEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846901629     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2006.08.015     Document Type: Article

References (34)

1. Postigo A.A., Garcia-Vicuna R., Laffon A., and Sanchez-Madrid F. The role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Autoimmunity 16 (1993) 69-76
2. Ospelt C., Neidhart M., Gay R.E., and Gay S. Synovial activation in rheumatoid arthritis. Front Biosci 9 (2004) 2323-2334
3. Milner J.M., and Cawston T.E. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 4 (2005) 363-375
4. Smeets T.J., Barg E.C., Kraan M.C., Smith M.D., Breedveld F.C., and Tak P.P. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 62 (2003) 635-638
5. Sandberg M., and Vuorio E. Localization of types I, II, and III collagen mRNAs in developing human skeletal tissues by in situ hybridization. J Cell Biol 104 (1987) 1077-1084
6. Poole A.R., Rizkalla G., Ionescu M., Reiner A., Brooks E., Rorabeck C., et al. Osteoarthritis in the human knee: a dynamic process of cartilage matrix degradation, synthesis and reorganization. Agents Actions Suppl 39 (1993) 3-13
7. Eyre D.R. The collagens of articular cartilage. Semin Arthritis Rheum 21 (1991) 2-11
8. Fernandes R.J., Schmid T.M., and Eyre D.R. Assembly of collagen types II, IX and XI into nascent hetero-fibrils by a rat chondrocyte cell line. Eur J Biochem 270 (2003) 3243-3250
9. Peltonen L., Halila R., and Ryhanen L. Enzymes converting procollagens to collagens. J Cell Biochem 28 (1985) 15-21
10. Sandell L.J., Morris N., Robbins J.R., and Goldring M.B. Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide. J Cell Biol 114 (1991) 1307-1319
11. Zhu Y., Oganesian A., Keene D.R., and Sandell L.J. Type IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-beta1 and BMP-2. J Cell Biol 144 (1999) 1069-1080
12. Mackintosh D., and Mason R.M. Pharmacological actions of 17 beta-oestradiol on articular cartilage chondrocytes and chondrosarcoma chondrocytes in the absence of oestrogen receptors. Biochim Biophys Acta 964 (1988) 295-302
13. Ishikawa T., Nishigaki F., Christgau S., Noto T., Mo J., From N., et al. Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol 31 (2004) 1174-1179
14. Johansen J.S., Olee T., Price P.A., Hashimoto S., Ochs R.L., and Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 44 (2001) 826-837
15. Schaller S., Henriksen K., Hoegh-Andersen P., Sondergaard B.C., Sumer E.U., Tanko L.B., et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol 3 (2005) 553-580
16. Sondergaard B.C., Henriksen K., Wulf H., Oestergaard S., Schurigt U., Bauer R., et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage (2006) [Epub ahead of print]
17. Hui W., Cawston T., and Rowan A.D. Transforming growth factor beta 1 and insulin-like growth factor 1 block collagen degradation induced by oncostatin M in combination with tumour necrosis factor alpha from bovine cartilage. Ann Rheum Dis 62 (2003) 172-174
18. Oestergaard S., Chouinard L., Doyle N., Karsdal M.A., Smith S.Y., Qvist P., et al. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage (2006) [Epub ahead of print]
19. Garnero P., Landewe R., Boers M., Verhoeven A., Van Der Linden S., Christgau S., et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 46 (2002) 2847-2856
20. Rousseau J.C., Zhu Y., Miossec P., Vignon E., Sandell L.J., Garnero P., et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 12 (Jun 2004) 440-447
21. Rebuck N., Croucher L.J., and Hollander A.P. Distribution of two alternatively spliced variants of the type II collagen N-propeptide compared with the C-propeptide in bovine chondrocyte pellet cultures. J Cell Biochem 75 (1999) 13-21
22. Genant H.K. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 75 (1983) 35-47
23. Fledelius C., Kolding I., Qvist P., Bonde M., Hassager C., Reginster J.Y., et al. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Scand J Clin Lab Invest 57 (1997) 73-83
24. McCarthy T.L., Ji C., and Centrella M. Links among growth factors, hormones, and nuclear factors with essential roles in bone formation. Crit Rev Oral Biol Med 11 (2000) 409-422
25. McQuillan D.J., Handley C.J., Campbell M.A., Bolis S., Milway V.E., and Herington A.C. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J 240 (1986) 423-430
26. Schachar N.S., Novak K., Hurtig M., Muldrew K., McPherson R., Wohl G., et al. Transplantation of cryopreserved osteochondral Dowel allografts for repair of focal articular defects in an ovine model. J Orthop Res 17 (1999) 909-919
27. Dreier R., Grassel S., Fuchs S., Schaumburger J., and Bruckner P. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp Cell Res 297 (2004) 303-312
28. Fukui N., McAlinden A., Zhu Y., Crouch E., Broekelmann T.J., Mecham R.P., et al. Processing of type II procollagen amino propeptide by matrix metalloproteinases. J Biol Chem 277 (2002) 2193-2201
29. McAlinden A., Zhu Y., and Sandell L.J. Expression of type II procollagens during development of the human intervertebral disc. Biochem Soc Trans 30 (2002) 831-838
30. Fukui N., Zhu Y., Maloney W.J., Clohisy J., and Sandell L.J. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am 85 (2003) 59-66
31. Park Y., Sugimoto M., Watrin A., Chiquet M., and Hunziker E.B. BMP-2 induces the expression of chondrocyte-specific genes in bovine synovium-derived progenitor cells cultured in three-dimensional alginate hydrogel. Osteoarthritis Cartilage 13 (2005) 527-536
32. Garnero P., Gineyts E., Christgau S., Finck B., and Delmas P.D. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 46 (2002) 21-30
33. Brittberg M., Lindahl A., Nilsson A., Ohlsson C., Isaksson O., and Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 331 (1994) 889-895
34. Plonczak M., Czubak J., and Kawiak J. Repair of articular cartilage defects with cultured chondrocytes on polysulphonic membrane: experimental studies in rabbits. Transplant Proc 38 (2006) 312-313